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SUMMARY
Adeno-associated viral vectors (AAV) have emerged as a gene delivery platform with 
demonstrated safety and efficacy in a handful of clinical trials for monogenic disorders. However, 
limitations of the current generation vectors often prevent broader application of AAV gene 
therapy. Efforts to engineer AAV have been hampered by a limited understanding of the structure-
function relationship of the complex multimeric icosahedral architecture of the particle. To 
develop additional reagents pertinent to further our insight into AAV, we inferred evolutionary 
intermediates of the viral capsid using ancestral sequence reconstruction. In silico derived 
sequences were synthesized de novo and characterized for biological properties relevant to clinical 
applications. This effort led to the generation of 9 functional putative ancestral AAVs and the 
identification of Anc80, the predicted ancestor of the widely studied AAV serotypes 1, 2, 8 and 9 
as a highly potent in vivo gene therapy vector for targeting liver, muscle, and retina.
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INTRODUCTION
Extensive preclinical studies have established a favorable safety profile for adeno-associated 
viral vector (AAV). In addition, AAV has enabled demonstration of in vivo gene therapy 
efficacy in animal models of disease with etiologies ranging from inherited, infectious to 
common complex (Hastie and Samulski, 2015; Schnepp and Johnson, 2014). Furthermore, 
recent early stage AAV clinical trials have led to the first demonstrations of clinical benefit 
in 2 forms of inherited blindness with AAV2 (Bainbridge et al., 2008; Jacobson et al., 2012; 
MacLaren et al., 2014; Maguire et al., 2008) and hemophilia B with AAV8 (Nathwani et al., 
2011). One treatment based on AAV1 has been awarded a drug license by European 
regulators (Bryant et al., 2013). Based on these data, AAV has been proposed as a platform 
technology for therapeutic in vivo gene delivery.
AAV is a 25 nm non-enveloped icosahedral capsid virus carrying a 4.7 kb ssDNA genome 
flanked by inverted terminal repeats (ITRs). AAV classifies as a Dependoparvovirus genus 
within the Parvoviridae family. Its genome comprises genes encoding for replication (Rep), 
structural capsid (Cap) and assembly (AAP) proteins. AAV is a helper-dependent virus, 
requiring the heterologous cofactors to complete a replicative cycle that an adenovirus or 
herpesvirus can provide in the context of a co-infection. Replication deficient AAV can be 
generated by eliminating all viral coding sequence in cis, and providing those in trans during 
vector production. Particles generated in this manner can encode any type of transgene 
cassette that does not exceed the size of the genome of the wild type virus (approximately 
4.7 kb) and enable gene transfer in vitro and in vivo to multiple cell and tissue targets (Knipe 
and Howley, 2013).
The AAV particle is composed of three C-terminally overlapping Cap proteins named VP1, 
2, and 3. VP3, the smallest member of these structural proteins is necessary and sufficient 
for full capsid assembly through multimerization. VP1, required for particle infectivity, and 
VP2, reported to be redundant structurally or functionally, are embedded in the wild type 
T=1 viral architecture at a VP1:2:3 ratio of approximately 1:1:10. A total of 60 VP 
monomers assemble into a icosahedral capsomer along 2, 3, and 5-fold axes of symmetry 
(Knipe and Howley, 2013). Every monomer within the 60-mer structure interfaces with 7 
neighboring capsid monomers. High resolution crystallography studies identify a conserved 
core structure composed of an eight-stranded β-barrel motif and the αA helix as well as nine 
surface exposed domains (VR-I to -IX) which can vary between the known primate AAV 
serotypes (DiMattia et al., 2012; Xie et al., 2002).
The structural diversity of natural AAVs is thereof largely contained within the nine surface 
regions of the capsid, which functionally results in divergent receptor binding properties, 
post-entry trafficking, host response, and gene transfer efficiency to various cell and tissue 
targets. Structural determinant for many of these properties have largely remained elusive 
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with a few notable exceptions: receptor binding motifs for certain serotypes (Bell et al., 
2012; Kern et al., 2003; Wu et al., 2000), phospholipase activity and nuclear localization 
activity on VP1,2 unique domains (Girod et al., 2002; Grieger et al., 2006), a limited number 
of docking sites for monoclonal antibodies (DiMattia et al., 2012), a motif enhancing T-cell 
immunogenicity (Vandenberghe et al., 2006), and a select number MHCI restricted T-cell 
epitopes (Mingozzi et al., 2007) have previously been mapped..
In an era of active clinical translation in AAV gene therapy, there is a desire to better 
understand the structure-function relationship of AAV within the constraints of the particle 
architecture in order to further model and modulate the pharmacology of this new class of 
drugs to improve transduction efficiency and specificity, alter tropism, and reduce 
immunogenicity. To enable mechanistic studies, map structural determinants of these 
phenotypes, and facilitate future rational AAV design aimed to mitigate the clinical 
limitations of the current technology, both reverse and forward genetic studies on AAV have 
been pursued. A wealth of naturally occurring AAV variants have been studied extensively 
and yielded large descriptive data sets (Gao et al., 2003; Gao et al., 2004; Gao et al., 2005). 
Forward genetic studies have resulted in important findings (Adachi et al., 2014; Asuri et al., 
2012; Bartel et al., 2012; Dalkara et al., 2013; Huttner et al., 2003; Koerber et al., 2008; Li 
et al., 2008; Lisowski et al., 2014; Maheshri et al., 2006; Mays et al., 2013; Perabo et al., 
2003; Shen et al., 2007; Wu et al., 2000) but often remain constrained by the limited 
tolerance for structural change of the rigid architecture of AAV (Adachi et al., 2014; Huttner 
et al., 2003; Lochrie et al., 2006; Mays et al., 2013; Shen et al., 2007; Vandenberghe et al., 
2009; Wu et al., 2000). Rational AAV design has therefore been difficult in structurally 
isolating and modulating vector phenotypes while retaining integrity and the desirable 
aspects of its innate function and biology of the particle.
Here, we hypothesized that the divergent AAV phenotypes and structural determinants 
underlying its biology and pharmacology could be mapped by recreating the evolutionary 
lineage of this virus. Under selective pressure, evolutionary intermediates along the lineage 
undergo phenotypic modulation while balancing these changes with the retention of 
structural and functional integrity that are expected to highlight evolutionary couplings and 
epistatic interactions. We used ancestral sequence reconstruction (ASR) methods to predict 
the amino-acid sequence of putative ancestral AAV capsid monomers using maximum-
likelihood (ML) methods (Finnigan et al., 2012). This led to the reconstruction of 9 nodes 
along the phylogeny of common ancestry of most of the AAV serotypes under clinical 
testing or consideration (AAV1–3 and 6–9). Through de novo gene synthesis of these 
reverse-translated ancestral capsid proteins, we demonstrate assembly and infectivity of 
members across this AAV lineage. The most distal presumed ancestor of the lineage, Anc80, 
was extensively characterized for its performance as a gene therapy vector and was 
demonstrated to be a potent broadly applicable vehicle for gene therapy with unique 
properties.
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In silico ancestral sequence reconstruction of AAV capsid protein
In lieu of attempting to isolate an intact ancestral viral sequence from proviral DNA or 
archeological samples, contemporary AAV sequence data was integrated through 
phylogenetic analysis and ML-ASR in order to infer the putative ancestral amino-acid 
sequence for the AAV Cap. A total of 75 sequences AAV serotype isolates and variants 
from previous biomining efforts (Gao et al., 2003; Gao et al., 2004) led to a robust AAV 
Cap phylogeny generated with PHYML (Guindon et al., 2010) with AAV5 as an outgroup. 
Only full length AAV capsids were included in this analysis that were (a) naturally 
occurring in primate populations, (b) previously demonstrated to assemble and infect 
efficiently, and (c) not known to have arisen through recombination events in its natural 
history, as traditional phylogenic analysis and ASR do not account for horizontal 
evolutionary events. The dendrogram in Figure 1 models the evolutionary path of AAV with 
early speciation of AAV4, and 5 serotypes, parallel to a single node, named Anc80, from 
which most known contemporary AAVs evolved. These serotypes include AAV1, 2, 8 and 
9, currently in human gene therapy trials. Nodes in this phylogeny were named Anc and 
numbered sequentially. To validate our approach, the Anc80 node was developed into a 
recombinant virus for possible use as a gene therapy vector (Figure 1).
Anc80 was chosen in part because the reconstruction of this node was highly informed by 
the abundance of naturally occurring and clinically relevant AAV descendants. Furthermore, 
Anc80 is embedded in the phylogeny of the Dependoparvoviridae with known helper-
dependent primate AAVs that arose prior to Anc80’s speciation (Figure 1) making it more 
likely that the ancestrally reconstructed particle retains the basic properties shared within 
this family. Using ML methods, a protein sequence prediction was derived for Anc80 based 
on calculated posterior probabilities for each residue in a particular position. In order to 
account for the uncertainty in selecting the appropriate amino-acid in each position, we 
aimed at generating all possible sequence permutations for positions with individual amino-
acid posterior probabilities with p≥0.3. A representation of this library, Anc80Lib, is 
illustrated in Figure 2A in a part-structural alignment with an AAV2 and AAV8 reference 
capsid sequence. Practically, this led to a probabilistic sequence space composed out of 
sequences for which most of the 736 Anc80 capsid amino-acid positions were fixed due to 
the high certainty in those positions by the ML-ASR, while for 11 positions 2 amino-acid 
options were provided, resulting in a sequence space encompassing 211=2048 permutations.
Structural and sequence alignment of Anc80Lib with extant AAVs and their X-ray 
crystallography data highlight significant divergence from currently known circulating 
AAV. The closest homologue as determined via BLAST search is rh.10, a rhesus macaque 
isolate within Clade E of the primate Dependoparvoviridae, which differs from Anc80Lib 
by minimally 7.8% which accounts for 58 divergent amino-acid positions (Figure 2B). 
AAV8 and AAV2 differ 8.7% and 12.0%, respectively and those 65–89 variable sites are 
distributed unevenly over the entire VP1 protein, including the VP1, 2 unique domains 
(Figure 2A, B). Divergence is highest in the hypervariable domains I, IV, VII, and VIII, both 
in terms of sequence as well as based on structural modeling of Anc80Lib clones in overlay 
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with AAV2 and 8 monomeric structures (Figure 2A, C). Mapping of the variable Anc80 
residues onto trimeric X-ray crystallography models of AAV2 and AAV8 in Figure 2D 
highlight most changes to be concentrated on the external surface of the virion, particularly 
on peak and flanks of the protrusions around the 3-fold axis of symmetry. However, a 
significant number of variable residues were also noted on the surface exposed domains 
outside of the 3-fold axis in addition to a smaller number of variations on the internal 
surface of the particle and on regions of Cap that are not resolved in the X ray structures.
Anc80 synthesis and basic characterization
Anc80Lib protein sequences were subsequently reverse translated and generated by gene 
synthesis in pooled library format. Capsid genes were cloned into an AAV packaging 
plasmid encoding AAV2 Rep into pAnc80Lib following which the library was deconvoluted 
clonally. Individual clones (named pAnc80LX, with X a consecutive number) were 
evaluated in isolation to avoid potentially interfering competitive interactions in a minimally 
divergent library population. A portion of individual Anc80 clones were Sanger sequenced 
verifying integrity and complexity requirements. Clonal Anc80 plasmids were co-
transfected with a ΔF6 adenoviral helper plasmid, an expression construct for AAP derived 
from AAV2 (AAP2), and ITR flanked expression construct encoding luciferase. A total of 
776 library clones were produced and inoculated at equal volume of producer cell lysate on 
HEK293 cells in a semi-high-throughput assay aiming to assess combined particle assembly 
and transduction efficiency. Approximately 50% of the Anc80 clones led to detectable 
signal over background in this rudimentary screening assay. Several lead candidates with 
highest luciferase signal progressed to sequencing confirmation and titration for DNaseI 
resistant genome containing particles (GC) and infectivity on HEK293 cells. Based on these 
results Anc80L65, the 65th Anc80Lib clone that was evaluated, was selected for further 
characterization. Anc80L65 vector yields from cell lysate are between 82–167% of AAV2 
yields, yet were depressed compared to the high yielding AAV8 (3–5% relative AAV8 
yields). In vitro infectivity on HEK293 is inferior to AAV2 however superior to AAV8 on a 
particle per cell basis.
Anc80L65 vector preparations were produced and purified on an iodixanol gradient at scale 
following traditional protocols and subjected to a variety of biochemical, biophysical, and 
structural analyses. Particles within a purified preparation of Anc80L65 were visualized 
under negative staining by electron microscopy (EM) (Figure 3A). Anc80L65 virions 
present as relatively uniform hexagonally shaped particles with a diameter of approximately 
20–25 nm, not unlike other AAV capsomers. Denatured particles resolved under SDS 
electrophoresis into 3 bands of 60, 72, and 90 kDa, in an approximate ratio of 1:1:10 
corresponding to the VP1–3 proteins from AAV2 and AAV8 particles (Figure 3B). 
Analytical ultracentrifugation (AUC) allowed us to determine the sedimentation coefficient 
of genome containing Anc80L65 at 88.9 S, slightly increased from AAV8’s (85.9 S) (Figure 
3C). This analysis permitted us further to determine the relative abundance of empty or 
lower density assembled particles, presumed to be lacking a vector genome, as well as 
overall purity. One concern was that inaccurate modeling of the ancestral capsid sequence 
may have resulted in a structure deficient in its ability to package genomes and would result 
in a skewed empty versus full ratio in Anc80L65 preparations. Results indicated 
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approximately 16% empty versus 85% full particles in our preparation, in line with 
observations with AAV8 (Figure 3C). Additionally, we hypothesized particle stability may 
be reduced due to suboptimal modeling of the ancestral capsid composition, and subjected 
the particle to heat stability assays which determined against our expectations Anc80L65 to 
be 15–30° C more heat stable that its presumed A AV2 and AAV8 (Figure 3D).
In vivo gene transfer and transduction of Anc80L65 in murine model
Next, we evaluated the ability of Anc80L65 packaged transgenes to be delivered and 
expressed from 3 clinically relevant target tissues and routes of administration (ROA) in the 
C57Bl/6 mouse: (a) liver following a systemic injection, (b) skeletal muscle following direct 
intramuscular injection, and (c) a subretinal injection for outer retina targeting. Large scale 
preparations of Anc80L65 were produced alongside with AAV2 and AAV8 controls with 
reporter genes and were injected at equal doses for liver, muscle and retina directed gene 
transfer in adult male C57Bl/6 mice. Expression, presented in Figure 4, was monitored 
qualitatively (eGFP and/or LacZ for all three target tissues and quantitatively via serum 
ELISA measurement of the secreted hA1AT (liver) at various time points. Liver directed 
gene transfer was observed to be robust via 2 routes of administration and transgenes 
(Figure 4A, B, C). Analogously to AAV8, hepatocytes were targeted efficiently as observed 
by LacZ and GFP staining surpassing the limited permissively described for AAV2 (Nakai 
et al., 2005; Nakai et al., 2002). Quantitatively, Anc80 demonstrated similar efficiency of 
transduction to AAV8 by intracellular reporter and a secreted serum protein transgene 
product. Dose ranging studies demonstrated a linearity of gene transfer with dose above 1010 
GC/mouse but a threshold below which linearity was not maintained for hA1AT (and less 
obvious by eGFP) (Figure 4B, C). A biodistribution study at the high dose of 5×1011 GC/
mouse was conducted at day 7 and 28 post injection to evaluate tissue distribution of vector 
genomes in liver, heart, spleen, kidney, and lung of Anc80L65 alongside AAV8 as a control 
(Table S1). Results show similar ranges of gene transfer of Anc80 to AAV8 in the tissues 
tested, with moderate increases for Anc80L65 in spleen, heart, and lung. Via direct skeletal 
intramuscular injection, Anc80 efficiently targeted myofibers proximal to the injection site 
and longitudinally extending across the fiber (Figure 4A and Figure S1). Retinal 
transduction after subretinal injection is efficient in targeting the retina pigment epithelium 
(RPE), as was the case in AAV2 and AAV8 as previously noted (Auricchio et al., 2001). 
Photoreceptor targeting, a more difficult cell target, as is documented for AAV2, was 
observed with AAV8 and Anc80L65 (Allocca et al., 2007). While both AAV8 and 
Anc80L65 targeted the majority of photoreceptor cells, transduction with Anc80L65 leads 
consistently to higher expression levels per cell. A limited number of cells in the inner retina 
were also observed to be GFP positive by Anc80L65 transduction (Figure 4A).
Anc80L65 gene transfer and expression in non-human primate liver
Given the robust hepatotropism of Anc80L65 in mice, we aimed at evaluating gene transfer 
of Anc80L65 in a large animal model. Six female rhesus macaques that were previously 
enrolled in prior studies unrelated to AAV were injected via saphenous vein with either 
AAV8 or Anc80L65 at a clinically relevant dose of 1012 GC/kg (Table S2). AAVs 
expressing the rhesus cDNA for the β subunit of the chorionic gonadotropin (rhCG), a 
transgene product that the animals are tolarized for in order to avoid a non-self transgene 
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immune response, was used as transgene. Animals were selected based on NAB to AAV8 
and Anc80L65 with serum levels prior to injection below 1/4 titer. Gene transfer was 
assessed by Taqman qPCR for vg of total liver DNA (caudal lobe) 70–71 days following 
injection (Figure 4D). Surprisingly, 2 out of 3 control AAV8 injected animal had 
underwhelming gene transfer (<0.1 vg/dg) likely due to low level NAB at the time of 
injection undetectable by standard NAB assays as reported in previous studies. One AAV8 
animal, presumably with no or minimal NAB to AAV8 demonstrated gene transfer levels 
for liver within the expected range of 0.81 vg/dg. Anc80L65 gene transfer was efficient with 
3 animals yielding hepatic transgene copy numbers ranging from 0.73–3.56 vg/dg. Liver 
expression was monitored via quantitative RT-PCR (Figure 4E): Anc80L65 led to 
expression superior to the AAV8, and achieved rhCG transcript levels between 13–26% of 
total GAPDH mRNA amounts in all liver lobes.
Safety, Immunology, and Toxicology of Anc80L65
The consideration to use any efficient gene delivery vector system for therapeutic 
application requires extensive evaluation of its safety for clinical use. In addition, the use of 
a novel agent which may approximate an ancestral state of a Dependoparvovirus may 
further raise those concerns. Here, in a non-formal preclinical setting, we examined several 
important aspects that may limit Anc80L65 from a safety perspective. Animal expression 
studies (Fig. 4) were monitored for obvious signs of toxicity during the in life phase of the 
study and for target tissue specific toxicity. No notable adversity was found to be associated 
with the vector injection. Briefly, vector administration following intraperitoneal (maximum 
dose tested [mdt]: 3.9 × 1010 GC/mouse), retro-orbital vein injection (mdt: 5 × 1011 GC/
mouse), subretinal (mdt: 2 × 109 GC/eye), intravitreal (mdt: 2 × 109 GC/eye), and direct 
intramuscular (mdt: 1010 GC/mouse) were not observed to have overt toxicity. A more 
direct assessment was performed in a high dose intravenous injection of 5 × 1011 GC/mouse 
(equivalent to approximately 2 × 1013 GC/kg) of Anc80L65.TBG.eGFP alongside the 
following controls: (a) AAV8 with the same transgene cassette, and (b) an equal volume 
saline injection. Mice were phlebotomized pre-injection, 2 hours (h), 1, 3, 7, 14, and 28 days 
(d) post injection and blood was analyzed for Cell Blood Counts (CBC) and Serum 
Chemistry (Chem) (Tables S3, S4). CBC/Chem values for Anc80L65 were within normal 
range or comparable to controls. Serum from the 2 h, 24 h, 3 d, and 7 d time points were 
further evaluated for cytokines as a measure of innate immune response to the vector 
antigens by multiplex 23 cytokine analysis (Table S5). Cytokines for Anc80L65 were 
overall concordant with those for saline and AAV8 control serum, and no major cytokine 
elevations or decreases were observed, however in some instances were moderately outside 
the ranges set by the saline control values in a manner that was more apparent for Anc80L65 
than AAV8. Similar analyses were performed on the blood from the rhesus studies described 
in Figure 4 D and E. Analogous to the mouse studies, CBC and Chem values did not 
demonstrate e signs of toxicity related to the AAV8 or Anc80L65 test article (Tables S6, S7)
Pre-existing immunity to AAV serotypes is known to block gene transfer, and may put the 
patient at risk for adversity due to recall of memory T-cells toward vector antigens shared 
with the naturally occurring wild type virus involved in the primary infection. We used high 
titer rabbit antiserum raised against AAV serotypes 1, 2, 5, 6.2, 8, 9, and rh.32.33. We 
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furthermore included rh.10 as its sequence is most closely homologous to Anc80L65 
differing in 8.6% of residues. In Figure 5A, sera were tested for their ability to neutralize 
Anc80L65 versus the homologous vector capsid it was raised against. Results demonstrate 
no cross-reactivity to the structurally highly divergent AAV5 and rh32.33, while AAV2, 6.2, 
and 8, presumed descendants of Anc80L65 demonstrated low level cross-reactivity with 
between 16–1024 fold reduced neutralization as compared to the homologous virus. Among 
Anc80 lineage members, no cross-reactivity was observed above the limit of sensitivity for 
AAV9 and rh.10. Next, we aimed at validating these results in an in vivo model for 
neutralization by pre-immunizing animals for AAV8 via intramuscular route, and 25 days 
following the immunization assessing the neutralization of Anc80L65 following intravenous 
injection in comparison to AAV8 (Figure 5B). Neutralization was complete for AAV8 in the 
AAV8 pre-immunized animals. Anc80L65 was neutralized in 2/5 animals, yet demonstrated 
between 60–117% of transduction in 3/5 animals notwithstanding demonstrated AAV8 
NAB in those animals. These results demonstrate partial cross-reactivity of Anc80L65 with 
AAV8 in rabbit and mouse.
AAV Lineage analysis and reconstruction
Strengthened by the successful synthesis of Anc80L65 based on ASR and its demonstration 
as producible, stable, and highly infectious agent for gene therapy, we aimed at providing 
additional validation of our approach and modeling methodology by reconstructing the 
lineage of AAV further. Our ambition generating this additional set of reagents was to 
provide structural intermediates of phenotypically distinct AAVs permitting empirical 
evaluation of the structure-function relationship within this viral family and highlighting 
important epistatic couplings informative to future AAV rational design approaches. A total 
of 8 additional evolutionary intermediates of AAV were reconstructed by ASR and 
synthesized in the laboratory (Figure 1): Anc81, Anc82, Anc83, Anc84, Anc110, and 
Anc113 were resolved in the branching leading toward AAV7, 8, and/or 9, while Anc126 
and Anc127 are positioned in the natural history of AAV1, 2, and/or 3. For each of these, the 
sequence was determined by selecting the amino-acid with highest posterior probability per 
position (Fig. S2). First, we determined GC viral vector yields following HEK293 standard 
triple transfection by Taqman qPCR. Results, shown in Figure 6A, demonstrate increased 
productivity from Anc80 as the putative ancestor in the AAV7–9 lineage, in line with the 
higher production yields of those serotypes such as AAV8. The AAV1–3 branch did not 
present yield increases, and a very poor particle yield for Anc126. It is possible that Anc126 
yields can be improved upon through leveraging the statistical space as was the case for 
Anc80. It is equally however likely that Anc126 ASR is less informed due to under-
sampling of this branch of the AAV phylogeny. We further tested infectivity of the produced 
particles at equal particle doses in vitro on HEK293 by GFP and luciferase. All newly 
synthesized Anc vectors demonstrated infectivity, however at varying degrees (Figure 6B). 
In the AAV7, 8 & 9 lineage infectious titers were overall depressed and more similar to the 
AAV8 phenotype than that of Anc80. Anc127, the only intermediate in the Anc80 to AAV2 
lineage that could be tested at equal dose demonstrated declined transduction efficiency as 
compared to both Anc80 as well as AAV2. We further tested the heat stability profile of 
selected evolutionary intermediates in both branches of this lineage (Figure 6C). 
Interestingly Anc81 and Anc82 demonstrated high, yet moderately decreased melting 
Zinn et al. Page 8













temperature in a thermostability assay compared to Anc80L65, suggesting a gradual 
reduction of particle denaturation temperature with evolutionary age in this branch. In 
contrast, Anc127 demonstrated an even further increase from the already highly 
thermostable Anc80L65 vector.
Lastly, we explored the ability of ASR to disrupt known epitopes to AAV2. Only few B or 
T-cell epitopes have been mapped on AAV2 to date, all of which were mapped onto 
Anc80L65, Anc126, Anc127, and AAV2, representing the AAV2 lineage. The introduction 
of the sequential mutations between these putative evolutionary intermediates highlights in 
Figure 5C the overlap between the mutations and 2/4 human T-cell epitopes (Mingozzi et 
al., 2007), and 2/2 mouse B-cell epitopes (Gurda et al., 2012). These data highlight the 
potential of ASR to be used as a method to eliminate or modulate antigenic regions onto the 
AAV capsid, and may suggest immunity was a major selective pressure in the natural 
history of AAV.
DISCUSSION
Forward genetics studies on multimeric complex protein assemblies are intricately difficult 
due to the structural constraints imposed by secondary, tertiary, and quaternary interactions 
within and between monomers. Many virus form icosahedral capsids as an economical way 
to build larger complex shells from smaller repeat units without expending excessive genetic 
bandwidth. These 20-faceted structures are composed of 60, or multiples thereof, subunits, 
each of which can integrate one or more structural viral proteins. As a function of its 
triangulation number and monomer size, Parvoviridae, with AAV as a member, are 
therefore one of the smallest known virus with a capsid diameter in the 18–26 nm range 
(Knipe and Howley, 2013). In order for the virus to evolutionary maintain the benefits from 
this icosahedral structure, sequence permutations are iteratively evaluated, not unlike 
traditional forward genetic structure-function experimentation in a laboratory setting. Only 
those monomer conformations that efficiently integrate in the icosahedral structure and can 
provide a selective advantage are able to persist, ultimately driving speciation.
Here, we sought to investigate, reconstruct, and learn from this natural experimentation 
using the simplest of all icosahedral viruses, AAV, as a model. Here, we aimed at 
reconstructing the viral lineage of AAV, a commonly used virus for gene transfer through 
methodologies similar to Gullberg et al.’s reconstruction of Coxsackievirus putative ancestor 
(Gullberg et al., 2010). First, putative ancestral sequences of the AAV capsid protein was 
inferred using in silico phylogenetic and statistical modeling. Next, these sequences were 
synthesized de novo and using traditional virological technique the virions derived were 
evaluated for assembly and infectivity. We anticipated the solution space containing 
monomers that structurally integrate into a viral particle and result in infectious virions to be 
minimally small, given that the limited knowledge base on intra- and intermolecular epistatis 
or the minimal structural components of AAV that constitute infectivity or function. To 
hedge for this anticipated low probability of success, ML statistics were used to inform us; 
we generated a probabilistic sequence space providing margins to account for the ambiguity 
of the heuristics used. Screening of the vector library that emerged from this sequence space 
yielded Anc80L65: a viral-like, AAV-like particle via structural and biochemical measures 
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(Figure 2, 3) and 8.6% or 64 AA divergent from the closest known AAV sequence. 
Anc80L65 furthermore demonstrates high stability, unlike any of the tested extant 
descendants. Anc80L65 is infectious (Fig. 6B), and is efficient as a gene transfer vehicle in 
murine models for retina, liver, and muscle targeting and in non-human primates for liver 
directed gene transfer (Fig. 4). Its utility as a gene transfer vector was further evaluated in a 
set of safety studies which did not illustrated vector-related toxicity concerns (Tables S1–7).
An important property of a gene transfer vector for clinical utility is its ability to be 
produced efficiently. Vector yields are a function of the production system and innate 
structural assembly efficiencies. Anc80L65, exceeding our expectation, yields GC particles 
in approximately equivalent ranges to AAV2, the most studied clinical AAV technology to 
date. AAV2 yet is reduced compared to other high yielding AAVs (Fig. 6A). In an attempt 
to understand the variation in particle yield, we tested the hypothesis that this is due to 
reduced stability. In contrast, Anc80L65 was thermostable up to temperatures of 92° C 
compared to 68° and 72° C for AAV2 and 8. It is possible that this high thermostability 
informs us on a higher activation energy threshold needed for Anc80L65 to dissociate, and 
possibly inversely, to assemble. Further work is required to investigate this fascinating 
relationship. Another possibility relates to what can be referred to as the ‘Back to the 
Future’ concern; here we present data on an attempt to take the ancestral state of a single 
virion component, and bring it to life in an otherwise fully contemporary context. This 
process conceptually ignores the possibility that coevolution took place with other AAV 
components (e.g. AAP, ITR), helper functions provided by adenovirus or other helper virus 
functions, and the host cell. If indeed such co-evolution occurred, those heterologous 
ancestral components may be required to bring full functionality to Anc80L65, or any 
ancestral AAV capsomer. To date, no data is available to suggest indeed such a missing 
ancestral link is prohibiting further potentiation of Anc80L65 in its assembly, packaging, or 
transduction biology.
Building on the validation that Anc80L65 brought to our methodology, we expanded the set 
of evolutionary intermediates for experimentation to 8 additional Anc particles along the 
lineage toward AAV1–3 and 7–9 (Figure 1). We demonstrate assembly, packaging, and in 
vitro infectivity of these particles. Particularly along the AAV8 branching from Anc80L65, 
our data suggest an increased productivity of viral yields illustrating that close putative 
descendants of Anc80L65 were able to overcome the production limitation discussed above 
(Figure 6).
In addition to ASR providing a novel methodology to synthetically derive viral vectors with 
novel biology, as demonstrated for Anc80L65, the availability of functional intermediates of 
divergent extant viruses may enable the elucidation of relevant questions to the unique 
biology of the distinct AAV serotypes. In turn, these data may ultimately make possible 
structure-guided design of AAV, and tailor it to the specific requirement of a clinical 
application. Our approach may furthermore shed light on the evolutionary pressures of AAV 
along its modeled natural history. One such presumed evolutionary pressure is of highest 
concern for gene therapy applications. Since AAV is widely circulating in humans, long-
lived memory T and B-cell responses pose a problem for gene therapy across broad 
populations. Indeed, individuals with pre-existing immunity (PEI) to AAV (in some 
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populations over 50%), are currently excluded from participating in many AAV clinical 
trials as no adequate alternative mitigation strategies exist to address the problem (Louis 
Jeune et al., 2013). Here, we demonstrate that ASR is able to modulate known epitopes that 
govern B and T-cell PEI to novel antigenic sites and thereby possibly reduce the affinity of 
MHCI-TCR and virus-NAB interactions (Fig. 5). Unlike rabbit vaccination experiments as 
in Figure 5A, human PEI is highly cross-reactive across many serotypes, making it difficult 
for any AAV-like particle escape this wide breadth PEI in humans (Brantly et al., 2009; 
Calcedo et al., 2009). To evaluate seroprevalence of Anc vectors and how these data inform 
a gene therapy outcome, a more robust and predictive assay is required as are extensive 
seroprevalence studies. Indeed our data highlights traditional NAB assays poorly correlating 
with in vivo neutralization (Figure 4D and 5B), as was previously noted (Wang et al., 2010).
In conclusion, ASR is shown to be a powerful methodology to generate functional 
intermediates of complex and structurally constrained biological assemblies, here 
exemplified for an icosahedral virus, AAV. The ancestral reconstruction of Anc80L65, the 
common putative ancestor of AAV1–3 and 7–9, yielded a highly potent vector particle with 
potential use in gene therapy applications via in silico and synthetic biology methods. The 
resolution of the lineage from Anc80 toward these extant serotypes provides a toolset of 
gene transfer reagents that further can help elucidate complex structure-function 
relationships within AAV and eventually may facilitate structure-based design of this 
potential new class of genetic drugs.
EXPERIMENTAL PROCEDURES
Ancestral Sequence Reconstruction of AAV Capsids
These studies were conducted following approval of the Harvard Medical School 
Institutional Biosafety Committee (Committee on Microbiological Safety) which included 
considerations of dual use of the vector reagents described here. Ancestral capsid sequences 
were reconstructed using maximum-likelihood methods as in (Finnigan et al., 2012) An 
alignment of 75 AAV capsids (Genbank accession numbers in supplement) was generated 
using PRANK v.121002 using the –F option (Loytynoja and Goldman, 2005), (Loytynoja 
and Goldman, 2008) and the JTT+F+G model was determined to be the phylogenetic model 
of best fit through the Aikake Information Criterion as implemented in ProtTest3 (Darriba et 
al., 2011). The alignment and best-fit model were then used to infer a phylogeny through 
PhyML 3.0 (Guindon et al., 2010) which was evaluated through the approximate likelihood-
ratio test (aLRT) (Anisimova and Gascuel, 2006) as implemented in PhyML. Ancestral 
capsid sequences were then inferred using PAML 4.6 (Yang, 2007) through the Lazarus 
package developed by the Thornton group. Sequences are available through GenBank 
(KT235804-KT235812). In order to compensate for the uncertainty inherent to the 
reconstruction, a script was written to assess the computed posterior probabilities to identify 
ambiguously reconstructed sites. Positions were considered ambiguous along the 
reconstructed capsid sequence if more than one amino-acid had a posterior probability 
greater than 0.3. Eleven such sites were identified on Anc80, each with two probable amino 
acids. These eleven dimorphic sites were then incorporated into a DNA library using the 
codons from a modern virus (rh.10). Because the reconstruction did not consider the 
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coevolution of AAP and the capsid, the AAP open-reading frame was ablated by changing 
the non-canonical CTG start codon to CAG during library design. In addition, another 
downstream ATG also in the AAP ORF was ablated by changing the codon to AAG. These 
modifications did not alter the amino-acids in the cap ORF. The DNA library was then 
synthesized by DNA2.0 and subsequently subcloned into expression vectors via restriction 
enzyme digest and ligation.
In vitro Characterization of AAV Ancestral Lineage Vectors
To identify and characterize functional AAV capsids within Anc80Lib, individual clones 
from the subcloned DNA library were isolated and used to produce luciferase-containing 
vector in either 6-well or 96-well with AAP2 provided in trans. Crude vector was isolated by 
filtering cell lysate through a 0.4 µm filter after 48 hours had elapsed since transfection. 
Next, equal volumes of this crude vector preparation were added to 96-well plates confluent 
with HEK293 cells which were evaluated for their luciferase activity an additional 48 hours 
later. In total, 776 clones were evaluated. Crude preparations of vector containing a CMV 
driven luciferase were produced by triple transfection in a 6-well format, supplementing 
AAP in trans to ancestral AAV vectors. In total, three different independent biologic 
replicates were produced per vector. DNAseI resistant transgenes were quantified as above. 
These crude preparations of virus were each then evaluated for their ability to transduce 
HEK293 cells in technical triplicates at an MOI of 1.9E3 GC/cell with the exception of 
Anc126, which was added at MOIs between 2.1E2 and 3.5E2 gc/cell. After 48 hours had 
elapsed, the transduced cells were assessed for luciferase via luminescence assay.
AAV Vector Preparation
Large-scale polyethylenimine (PEI) transfections of AAV cis, AAV trans, and adenovirus 
helper plasmid were performed in a 10-layer hyperflask (Corning) with near confluent 
monolayers of HEK 293 cells. Plasmids were transfected at a ratio of 2:1:1 (260 µg of 
adenovirus helper plasmid/130 µg of cis plasmid/130 ug of trans plasmid). Transfections for 
production of Anc vectors were supplemented with pAAP2 in equivalent amounts as the 
AAV cis plasmid. PEI Max (Polysciences, Warrington, PA)/DNA ratio was maintained at 
1.375:1 (w/w). The transfection and downstream purification process were performed as 
previously described (Lock et al., 2010). DNAseI-resistant vector genomes copies were used 
to titrate AAV preparations by TaqMan qPCR amplification (Applied Biosystems 7500, Life 
Technologies) with primers and probes detecting promoter, transgene, or poly-adenylation 
signal coding regions of the transgene cassette. The purity of the large-scale preparations 
was evaluated by SDS-PAGE gel electrophoresis.
In vivo gene transfer (mouse)
C57BL/6 male mice (6–8 weeks old) were purchased from Charles River Laboratories 
(Wilmington, MA) and kept at the Schepens Eye Research Institute (SERI) Animal Facility. 
All animal procedures were performed in accordance with protocols approved by the 
Institute of Animal Care and Use Committees at SERI. For liver directed studies, Male 
C57BL/6 mice were each injected retro-orbitally (150µl) or intraperitoneally (100µl). Blood 
was collect via submandibular bleeds using GoldenRod animal lancets (MEDIpoint, Inc.). 
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Animals were euthanized, and livers were collected. Expression of lacZ was assessed using 
a β-Gal staining kit (Life Technologies, Cat. No. K1465-01). In skeletal muscle studies, 
male C57BL/6 mice were injected into the rear-right gastrocnemius muscle (50 uL). Retinal 
studies were performed by subretinal injection of male C57BL/6 mice (2 uL).
In vivo gene transfer (nonhuman primate)
Experiments with rhesus monkeys were performed at New England Primate Research 
Center. All experimental procedures were approved by the Office for Research Subject 
Protection, Harvard Medical Area (HMA) Standing Committee on Animals, the Harvard 
Medical School Institutional Animal Care and Use Committee. Animals were sedated with 
ketamine or telazol in combination with dexdomitor. AAV was administered intravenously 
via the saphenous vein in a 20 ml volume at an approximate rate of 1ml/min. After 
recovering from the injection, the animals were monitored clinically for general wellbeing 
and followed for 2 months. During this time phlebotomies were performed at regular 
intervals to evaluate immune response to AAV and toxicity. After 70 days monkeys were 
euthanized, and liver samples were harvested. Tissue was harvested in RNALater (Life 
Technologies).
Additional detail on the experimental procedures is provided in detail in the supplement.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Phylogeny and ASR of AAV evolutionary lineage
Maximum-likelihood phylogeny relating 75 isolates of AAV). Red circles represent 
evolutionary intermediates reconstructed through ASR. Blue circle represents library of 
probabilistic sequence space around Anc80. Subclades are collapsed for clarity. Full 
phylogeny and sequence alignment is presented in Supplementary Figure S3 and S2.
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Figure 2. Sequence and structural analysis of Anc80 vectors
A. Sequence alignment of Anc80, AAV2 and AAV8 VP3 proteins. A structural alignment 
derived from the crystal structures of AAV2 (PDB 1LP3) and AAV8 (PDB 2QA0) VP3 and 
the predicted structure of Anc80L65 VP3 was generated with UCSF Chimera (Pettersen et 
al., 2004) and is represented in black print. The blue region is a non-structural alignment of 
the VP1/VP2 domains of AAV2, AAV8 and An80 (Notredame et al., 2000). Ambiguous 
residues in Anc80Lib are in red print with the lower position corresponding to Anc80L65 
residues. β-strands and α-helices are represented in green and yellow, respectively. The 
positions of the nine β-strands forming the AAV antiparallel β-barrel are depicted with plain 
arrows whereas the position of the conserved core α-helix is depicted with a dotted arrow. 
The approximate positions of variable regions (VR) I-IX are represented by the roman 
numerals above the sequence alignment. B. AAV Cap Sequence divergence matrix: Table 
represents above the diagonal the percent sequence divergence from selected AAV 
serotypes, as well as rh.10, most homologous VP1 sequence as by BLAST. Below the 
diagonal, the number of amino-acid differences per position is presented. C. 
Superimposition of AAV2 and AAV8 VP3 crystal structures with Anc80L65 VP3 predicted 
structure. The color code depicts the amino acid conservation between the 3 aligned 
sequences of panel A (red: highest conservation; blue: lowest conservation). Variables 
regions I-IX and C/M-termini are indicated in black. The approximate positions of the two, 
three and five-fold axis are represented by the black ellipse, triangle and pentagon, 
respectively. D. Structural mapping of amino-acid changes as compared to AAV2 (left) and 
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AAV8 (right) on VP1 trimer visualizing the external (top) and internal (bottom) of the 
virion. Colored residues are divergent in Anc80. Red colored residues are ambiguous via 
ASR and therefore dimorphic in Anc80Lib.
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Figure 3. Biophysical and biochemical characterization of Anc80L65
A. Negative staining Transmission Electron Microscopy (TEM) of Anc80L65 particles. B. 
Anc80L65 viral protein composition by SDS PAGE: Purified AAV preparations were 
analyzed by SDS-PAGE demonstrating similar incorporation levels of monomers VP1, 2, 
and 3. C. Anc80L65 sedimentation and empty:full particle profile: Sedimentation coefficient 
distributions were derived from the refractive index optical measurement systems during 
analytical ultracentrifugation of AAV8 and Anc80L65 iodixanol purified preparations. D. 
Anc80L65 thermostability: SDS page thermostability assessment of AAV particle illustrates 
dissociation into monomers for AAV2 and 8 at temperatures below 70°C for AAV2 and 8 
but requirin g 95°C melting temperatures for Anc80L65.
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Figure 4. Anc80L65 in vivo transduction biology
A, top panel: Mouse liver transduction and lacZ transgene expression comparison of 
AAV2, AAV8 and Anc80L65.TBG.nLacZ in liver 28 days after intraperitoneal delivery at a 
dose of 3.9 × 1010 GC (C57Bl/6, n=3). A, middle panel: AAV2, AAV8 and Anc80L65 
muscle tropism in mouse 28 days following an intramuscular delivery at a dose of 1010 GC 
to the rear-right thigh (gastrocnemius) (n=5). See also Figure S1. A, lower panel: 
Comparison of eGFP transgene expression between AAV2, AAV8, and Anc80L65 in the 
murine retina after subretinal delivery at a dose of 2×109 GC. AAV2 shows high affinity for 
RPE cells while both RPE and photoreceptors are targeted using AAV8 and Anc80L65 
vectors with Anc80L65 showing higher transduction efficiency compared to the AAV2 and 
8 (C57Bl/6, n=4 eyes). B. Qualitative dose response hepatic eGFP-expression analysis 
following dosing of 1011 (top panel), 1010 (middle panel), and 109 (bottom panel) GC 
comparing AAV-8 and Anc80L65 by retro-orbital intravenous injection in mouse. Both 
AAV8 and Anc80L65 lead to comparable eGFP expression at equal dose throughout the 
dose ranging. (C57Bl/6, n=3) C. Quantitative AAV dose response analysis measuring mouse 
serum levels of recombinant human alpha 1-antitrypsin (hA1AT) transgene expression from 
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AAV-8 (black symbols: square-1011 GC, circle-1010 GC, and four-square-109 GC) and 
Anc80L65 (grey symbols: diamond-1011 GC, square-1010 GC, and triangle-109 GC). 
(C57Bl/6, n=5). See also Table S1, S3, S4 and S5. D. Rhesus macaque liver gene transfer of 
AAV-8 and Anc80L65 expressing Rhesus chorionic-gonadotropin (rhCG) following 
saphenous vein injection of a dose of 1 × 1012 GC/kg. Genomic DNA was harvested from 
macaque liver-lobes and viral genome (vg) per diploid genome (dpg) was measured by 
qPCR assay. One AAV8 and all three Anc80L65 animals successfully received ~1–3 vg per 
diploid cell of the caudal liver lobe, while 2 AAV8 animals likely had low level NAB 
resulting in vector neutralization and limited liver gene transfer. See also Table S2, S6 and 
S7. E. Transgene mRNA expression of AAV8 and Anc80L65 in NHP caudal, right, left and 
middle liver-lobes by TaqMan probe-specific, quantitative reverse-transcriptase PCR (qRT-
PCR). Protein levels are not available due to lacking antibody and rhCG standards. 
Quantitation of rhCG transcript is normalized with endogenous GAPDH mRNA levels.
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Figure 5. Immunological characterization of Anc80L65
A. Rabbit anti-AAV serum cross-reactivity: Rabbit antiserum raised against AAV serotypes 
(Y-axis) was tested for NAB to Anc80L65 (grey bars) versus the homologous AAV serotype 
(black bars) in order to assess relative sero-cross-reactivity. Values (X-axis) represent 
highest dilution at which >50% neutralization is achieved. Phylogenetic relationship 
between immunizing serotypes is depicted schematically on the left. B. Mouse in vivo gene 
transfer cross-neutralization: C57Bl/6 mice received an IV injection of AAV8 or 
Anc80L65.CASI.EGFP.2A.A1AT 25 days following an IM injection with either saline or 
AAV8.TBG.nLacZ. 14 days following the second injections serum was titrated by ELISA 
for hA1AT expression. Table presents the relative hA1AT levels of the pre-immunized mice 
versus the non-immunized for each vector (% control), and the NAB titer dilutions for 
AAV8 (NAB8) and Anc80L65 (NAB80) 24 h prior to the second injection in the immunized 
group (n=5). C. A non-structural multiple sequence alignment between Anc80, Anc126, 
Anc127 and AAV2 VP3 sequences was generated using the Tcoffee alignment package. 
AAV2 trimer structure was generated using UCSF Chimera. The blue residues represent 
residues different from Anc80. The orange residues are defined T and B-cell epitopes on 
AAV2 (Gurda et al., 2013; Mingozzi et al., 2007). Green residues show the overlap between 
orange and blue residues to highlight mapped epitopes altered in the putative evolutionary 
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intermediates. Human T-cell epitopes with MHC haplotype: VPQYGYLTL (B*0702), 
SADNNNSEY (A*0101), YHLNGRDSL (B*1501), and TTSTRTWAL (B*0801). 
(Mingozzi et al., 2007) Mouse B-cell epitopes of defined AAV2 antibody SADNNNS plus 
RGNRQ for C37B Fab (Gurda et al., 2013). In bold are the residues within each epitope 
that are distinct between Anc80L65 and AAV80.
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Figure 6. AAV lineage reconstruction modulates production, infectivity, and thermostability
A. Production of nine ancestral and two extant viral vectors containing a luciferase reporter 
gene driven by a CMV promoter determined by qPCR. Error bars represent standard 
deviation of three biological replicates. B. Ancestral and extant viral vectors were used to 
transduce HEK293 cells at a particle to cell ratio of 1.9 × 103. Error bars represent standard 
deviation of three distinct lots of vector. *Anc126, was added at ratios between 2.1 × 102 
and 3.5 × 102 GC/cell due to low vector yield. Grey diverging arrow in A and B panels 
schematically illustrate AAV2 and AAV8 lineage phenotypic evolution. C. Sypro orange 
thermostability assay indicating denaturation temperatures of selected ncestral and extant 
AAV vectors. See also Figure S2.
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